PRLeap - Health News Releases

MED-EL Launches World's First Commercially Available Totally Invisible Cochlear Implant

Tue, 29 Sep 2026 05:00:00 PDT

September 29, 2026 (Innsbruck, Austria): MED-EL, a global leader in hearing implant technology, today announced the launch of TICI UNICO, the world's first and only commercially available totally invisible cochlear implant. Designed for people with severe-to-profound hearing loss, TICI UNICO enables continuous hearing 24 hours a day while remaining completely beneath the skin. It has received CE Mark approval and is being introduced in European markets.

Grünenthal partners with DKSH to bring four important pain medicines to eight new markets in Asia-Pacific

Sun, 27 Sep 2026 23:10:00 PDT

Aachen, Germany, 28 September 2026 Grünenthal, a global leader in pain management and research, and DKSH Business Unit Healthcare, a strategic healthcare business partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, today announced a new partnership agreement to bring four Grünenthal medicines, Qutenza®, Vimovo®, Palexia® and Zomig®, to Asia-Pacific, accelerating access to innovative pain therapies in the region.

Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich

Thu, 16 Jul 2026 00:15:00 PDT

Aachen, Germany, 16 July 2026 Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients.

Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy

Wed, 08 Jul 2026 00:45:00 PDT

Aachen, 08 July 2026 Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).

Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist

Mon, 29 Jun 2026 02:40:00 PDT

Grünenthal announced today that the company successfully concluded a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist.

The Virchow Prize 2026 Awarded for Pioneering Work on Ebola, Advancing Global Epidemic Preparedness and Fostering Global Solidarity

Tue, 02 Jun 2026 07:20:00 PDT

Jean-Jacques Muyembe and Peter Piot are being honored with the international award of 500,000 for exceptional life-long leadership spanning five decades since the first outbreak of Ebola

First Clinical Analysis of Electrochemotherapy in Prostate Cancer Shows 93% Response

Tue, 28 Apr 2026 02:40:00 PDT

Vitus Privatklinik reports the first and largest clinical cohort of electrochemotherapy in prostate cancer.

FUTRUE Neurosciences Reaches Major Milestone

Tue, 31 Mar 2026 02:30:00 PDT

FUTRUE Neurosciences has achieved its first milestone on its mission to become the global leader in modern brain-computer interfaces (BCIs) by 2030. BCIs establish a direct interface between the human brain and digital systems.

Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm

Thu, 05 Mar 2026 00:30:00 PST

Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment.

Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands

Mon, 02 Mar 2026 01:10:00 PST

Grünenthal today announced that it has acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', taking full ownership of the company formed through a joint venture and its portfolio of established medicines.

Grünenthal's proprietary NaV 1.8 inhibitor enters clinical development

Wed, 18 Feb 2026 01:30:00 PST

Aachen, Germany, 18 February 2026 Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.

Grünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex

Thu, 05 Feb 2026 07:10:00 PST

Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency)

Internationally honored: Prof. Dietmar Jürgen Daichendt receives honorary doctorate for pioneering achievements in osteopathy and manual medicine

Fri, 28 Nov 2025 04:00:00 PST

With this award, the conferring institution recognizes not only an outstanding scientific and clinical career, but in particular the unique academic milestones that Prof. Dr. Daichendt has set in Germany.

Hessian Minister President Boris Rhein presents the Broermann Medical Innovation Award

Tue, 18 Nov 2025 07:00:00 PST

Wiesbaden, November 18, 2025 At a festive ceremony in the Hessian State Chancellery, Dr. Carl June (University of Pennsylvania) and Dr. Michel Sadelain (Columbia University) were presented with the inaugural Broermann Medical Innovation Award by Minister President Boris Rhein.

Bella Dental Announces Wisdom Teeth Fridays, Ice Cream Saturdays for Teens

Thu, 16 Oct 2025 00:00:00 PDT

Designed specifically for teens and their busy parents, this innovative initiative makes wisdom teeth removal manageable, ensuring a quick recovery over the weekend so teens can return to school on Monday without missing a beat. After the procedure, each teen receives four pints of ice cream to enjoy during "Ice Cream Saturday" and Sunday.

Menno Place CEO Wins National HR Champion Award

Thu, 02 Oct 2025 00:00:00 PDT

Menno Place CEO, Sujata Connors, has won the 2025 Dentsu Canada Award for HR Champion (CEO) at this year's Canadian HR Awards! This award recognizes the CEO who has driven successful HR strategies from the top by putting people first and championing innovative HR values.

Dr. Carl June and Dr. Michel Sadelain are being awarded the Broermann Medical Innovation Award 2025

Thu, 18 Sep 2025 03:50:00 PDT

With prize money of one million euros, it is one of the most highly endowed medical awards in the world Awarded for groundbreaking pioneering work in cancer therapy using CAR-T cells Award Ceremony with Hessian Prime Minister Boris Rhein

Military Veterans Join Virtue Recovery to Expand Community Outreach with Hope and Support

Tue, 09 Sep 2025 00:00:00 PDT

Virtue Recovery has added two U.S. military veterans, Adam Khosroabadi and Chauncy Nash, to its Business Development Team. Their combined military service and personal recovery experience will expand outreach and support for veterans and others facing addiction, PTSD, and mental health challenges. This move strengthens Virtue Recovery's mission to provide compassionate, whole-person treatment across its nationally accredited centers.

Nominations for the Broermann Medical Innovation Award 2026 now open

Thu, 04 Sep 2025 08:30:00 PDT

The nomination period for the Broermann Medical Innovation Award 2026 has begun.

Grünenthal PRO is joining SHL Medical's alliance partnership network to offer final assembly service for Molly® autoinjectors

Thu, 04 Sep 2025 01:00:00 PDT

Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems. Through this collaboration, Grünenthal PRO will offer final assembly, packaging and labelling of Molly® autoinjector.

Bella Dental Group treats 100th patient using laser technology to save "hopeless" teeth

Tue, 15 Jul 2025 00:00:00 PDT

Bella Dental Group has announced a significant milestone in its local dental care, having successfully treated its 100th patient with its MVP-7 Multi-Variable Pulse laser, saving teeth and implants that were thought by patients to be "hopeless."

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

Mon, 02 Jun 2025 01:00:00 PDT

Aachen, Germany, 2 June 2025 Grünenthal today announced the acquisition of the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Over the next few years, Grünenthal and Lilly will work together to transfer the manufacturing to Grünenthal's production site in Santiago, Chile, that will supply Cialis® for Mexico, Brazil and Colombia moving forward.

Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase

Fri, 09 May 2025 03:00:00 PDT

Vienna, Austria May 9th 2025 Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications.

Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study

Tue, 29 Apr 2025 09:00:00 PDT

Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.

A Place to Heal: Virtue Recovery Center Stands with Veterans and Families Across the United States

Wed, 23 Apr 2025 00:00:00 PDT

Virtue Recovery Center in Las Vegas, NV, is stepping up as a critical ally in the fight against Veteran suicide and substance abuse by offering specialized, compassionate care for former service members in Nevada, Arizona, Texas, and Oregon.

DYMO® Partners with ELLKAY to Elevate the Healthcare Community with New Lab Enterprise Platform LKOrbit

Tue, 01 Apr 2025 08:00:00 PDT

The innovative cloud-based connectivity platform will expand outreach, streamline operations and increase revenue.

Nomination period for the Broermann Medical Innovation Award started

Fri, 17 Jan 2025 02:30:00 PST

The nomination period for the Broermann Medical Innovation Award has started.

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer

Thu, 09 Jan 2025 01:35:00 PST

Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.

Invisible Sensors Lead to Fewer Falls for Seniors - Menno Place and Esprit-ai Team Up for Pilot Project

Thu, 05 Dec 2024 00:00:00 PST

This technology enables care staff to more effectively track sleep quality, identify when residents need repositioning, and quickly respond to falls-all while maintaining privacy and without disturbing residents who are sleeping soundly.

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Thu, 07 Nov 2024 01:45:00 PST

- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2]